基因组亚型对初治EGFR突变NSCLC奥希替尼治疗颅内结局的影响
该多中心回顾性研究纳入470例初治EGFR突变NSCLC脑转移患者,接受一线奥希替尼±立体定向放疗(SRS)。24个月中枢神经系统(CNS)进展累积发生率在外显子19缺失为30%、L858R为47%、非典型突变为76%(p<0.001)。非典型突变和L858R的CNS进展风险显著高于外显子19缺失, upfront SRS可改善CNS结局,非典型突变获益最大。
要点
- 非典型EGFR突变和L858R的CNS进展风险显著高于外显子19缺失。
- 24个月CNS进展累积发生率:外显子19缺失30%,L858R 47%,非典型突变76%。
- upfront SRS与改善CNS结局相关,非典型突变患者获益最大。
核心结论
- 非典型和L858R EGFR突变患者CNS结局显著差于外显子19缺失患者。
- upfront SRS降低CNS进展风险,非典型突变患者获益最大。
- EGFR亚型可能帮助识别从SRS获益的患者。
研究设计与样本
- 多中心回顾性研究,从11家机构识别2016至2024年间470例初治EGFR突变NSCLC脑转移患者,接受一线奥希替尼±SRS。
- 主要终点为至CNS进展时间,采用Kaplan-Meier法分析时间-事件结局,Cox比例风险模型估计HR,Fine-Gray模型用于竞争风险终点。
主要发现
- 24个月CNS进展累积发生率:外显子19缺失30%(95%CI 25%-36%),L858R 47%(95%CI 39%-55%),非典型突变76%(95%CI 59%-87%),p<0.001。
- 多变量模型中,与非典型突变(HR=4.33,95%CI 2.72-6.91)和L858R(HR=1.68,95%CI 1.27-2.23)相比外显子19缺失的CNS进展风险更高。
- 外显子19缺失、L858R和非典型突变在局部和远处CNS进展及神经性死亡方面的分层结局相似。
- upfront SRS与改善CNS结局相关,非典型突变患者获益最大。
临床怎么用
- EGFR亚型可能帮助识别从upfront SRS获益的脑转移患者。
- 非典型突变和L858R患者CNS进展风险较高,需加强CNS监测。
局限性
- 回顾性研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Brain metastases cause considerable morbidity and mortality in EGFR-mutated NSCLC. The effect of EGFR alteration subtypes on central nervous system (CNS)-specific outcomes is poorly defined. METHODS: Patients with EGFR-mutated NSCLC and brain metastases treated with first-line osimertinib with or without stereotactic radiosurgery (SRS) were retrospectively identified from 11 institutions. The primary end point was time to CNS progression. Time-to-event outcomes were analyzed using Kaplan-Meier methods. Hazard ratios (HRs) were estimated with Cox proportional hazards models. Fine-Gray models were used for competing risk end points. RESULTS: Between 2016 and 2024, 470 patients were identified with the following alterations: exon 19 deletion (57%), L858R (33%), and atypical mutations (9.6%). At 24 months, cumulative incidence of CNS progression was 30% (95% confidence interval [CI]: 25%-36%) for exon 19 deletions, 47% (95% CI: 39%-55%) for L858R, and 76% (95% CI: 59%-87%) for atypical mutations (p < 0.001). In multivariable models, CNS progression was higher among patients with atypical alterations (HR = 4.33, 95% CI: 2.72-6.91) and L858R mutations (HR = 1.68, 95% CI: 1.27-2.23) compared with exon 19 deletions. Stratified outcomes for exon 19, L858R, and atypical mutations were similar across local and distant CNS progression and neurologic mortality. Upfront SRS was associated with improved CNS outcomes, with greatest benefit in patients with atypical alterations. CONCLUSION: Patients with atypical and L858R EGFR mutations had significantly worse CNS outcomes compared with those with exon 19 deletions. Upfront SRS reduced the risk of CNS progression, with the greatest benefit in patients with atypical alterations. EGFR subtype may help identify patients who benefit from SRS.
引用
- Miao EA, Wo E, Boe LA, et al. Impact of Genomic Subtype on Intracranial Outcomes in Treatment-Naive, EGFR-Mutant NSCLC With Osimertinib (IGnITE). J Thorac Oncol. 2026. PMID: 42520966. doi:10.1016/j.jtho.2026.104114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。